Idaho, Kansas and Missouri filed their complaint after the Supreme Court preserved access to mifepristone last year.

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

Health insurers, employers and pharmacy benefit managers may be insulated from the immediate effects of drug tariffs, but ...

To a great extent, the FDA leaves it to food companies to determine whether their ingredients and additives are safe. Some ...

Regulatory Activities: In April 2025, Sanofi and Regeneron Pharma received approval from the U.S. FDA for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic ...